Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma

Sağer, Sait; Akgün, Elife; Uslu-Beşli, Lebriz; Asa, Sertaç; Akovalı, Burak; Şahin, Onur Erdem; Yeyin, Nami; Demır, Mustafa; Abuqbeitah, Mohammad; Gülşen, Fatih; Sayman, Haluk; Sönmezoğlu, Kerim

doi:10.1097/mnm.0000000000001014

Cited by 13 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The evaluation of intrahepatic lesions was performed using liver magnetic resonance imaging (MRI), which was evaluated every 2 months until the patient stopped receiving regorafenib or died. According to the size of the lesion on the liver MRI and the extent of the lesion enhancement, the RECIST version 1.1 or mRECIST standard was used to evaluate the therapeutic effect (10,12). At the same time, the therapeutic effect was evaluated according to the changes in alpha fetoprotein (AFP) level (13,14).…”

Section: Efficacy and Safety Analysesmentioning

confidence: 99%

Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

Zhai¹,

Liu²,

Fu³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: There is lack of studies on sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma (HCC). This study was to explore the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib failure in HCC patients.Methods: This study was a retrospective, real-world study that included 50 HCC patients who received sequential regrafinib after sorafenib and lenvatinib failure. The safety and prognosis of two groups were compared. Results:The incidence of all grade and III/IV adverse events were 68% and 24%. According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 and modified (m) RECIST standards, the objective response rates (ORRs) after receiving regorafenib were 14.0% and 22.0%, respectively. The disease control rates (DCRs) were 62.0% and 60.0%, respectively. Based on different first-line targeted drugs, 50 patients were divided into sorafenib (n=22) and lenvatinib group (n=28). There was no differences between two groups except age and bilirubin. And there was no differences in other treatments before or after regorafenib.The baseline between two groups was basically same and had good comparability. There was no difference in incidence of all grade and III/IV adverse events, ORR and DCR between two groups (P>0.05). On long-term prognosis, total overall survival (TOS) in sorafenib and lenvatinib group were 23.0 (95% CI: 15.1-30.9) vs. 29.7 (95% CI: 21.4-38.1) months. The difference was statistically significant (P=0.041). Besides, regorafenib overall survival (ROS) in sorafenib and lenvatinib group were 11.7 (95% CI: 7.1-16.3) vs. 15.9 (95% CI: 8.3-23.5) months. The difference was statistically significant ( P=0.045). The regorafenib progression-free survival (RPFS) was 5.6 (95%

show abstract

Section: Efficacy and Safety Analysesmentioning

confidence: 99%

Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

Zhai¹,

Liu²,

Fu³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Both anatomical and metabolic response-rates have been related to OS. Yet, agreement between both methods is often lacking, with metabolic response generally overestimating anatomic response (101), as was also seen in our dose-response study. For radioembolization, metabolic response is believed to be the best assessment method, as this is not hampered by the presence of necrosis, cystic changes and hemorrhage, which can be the case with size evaluation (102).…”

Section: Discussionsupporting

confidence: 51%

Personalized radioembolization for colorectal cancer patients with liver metastases

Roekel¹

View full text Add to dashboard Cite

Chapter 1 Introduction and outline Chapter 2 Radioembolization Chapter 3 Quality of life in patients with liver tumors treated with holmium-166 radioembolization Chapter 4 Evaluation of the safety and feasibility of same day 166 Ho-radioembolization simulation and treatment of hepatic metastases Chapter 5 Mode of progression after radioembolization in patients with colorectal cancer liver metastases Chapter 6 First evidence for a dose-response relationship in patients treated with 166 Ho-radioembolization: a prospective study Chapter 7 Dose-effect relationships of holmium-166 radioembolization in colorectal cancer Chapter 8 The efficacy of coil-embolization to obtain intrahepatic redistribution in radioembolization: qualitative and quantitative analyses Chapter 9 Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization -a prospective, within-patient randomized study Chapter 10 Discussion Chapter 11 Summary Chapter 12 Nederlandse samenvatting Chapter 13 Addenda Review Committee List of publications Dankwoord Biography General introduction 8 Chapter 1Although there are many treatment options for colorectal cancer patients with liver metastases, colorectal cancer still remains the second most common type of cancer death worldwide (1).There is a wide variety in colorectal cancer incidence rates: the disease can be considered a marker of socioeconomic development and is more prevalent in countries with a high human development index. In developing countries, such as Russia and China, there is an increase in both incidence and mortality.In long-term developed countries, such as the United Kingdom and Denmark, there is an increase in incidence but a decrease in mortality. In other countries, such as France and the United States, a decrease in both incidence and mortality is seen. The rises in incidence can be explained by a change in dietary patterns (processed meat and alcohol drinks) and lifestyle factors (a sedentary lifestyle), as well as a consequence of screening programs that lead to early detection. The decreases in mortality are due to improved treatment strategies in developed countries (1).The incidence rate increases with age, with the median age worldwide being 66 years. Although the incidence and mortality rates decline for almost all age groups, in high-income countries, they are increasing for individuals younger than 50 years. This is likely due to the change in diet and lifestyle over the past decades, which is first reflected in incidence rates in young age groups. In this patient group, most patients present with advanced-stage disease. For patients with distant-stage disease, the five-year survival rate is only 14% (2). The first site of metastasis is the liver and up to 30% of patients with colorectal cancer develops hepatic metastases (3). For these patients, improved treatment strategies are needed.One of these improved treatment strategies is radioembolization.Radioembolization is a treatment option for patients with primary or secondary liver tumors. The treat...

show abstract

“…Em contrapartida, a análise da eficiência da resposta terapêutica pelos critérios de RECIST e PERCIST pode ser discordante entre si. Em uma comparação entre estes dois critérios, Sager et al 35 mostraram que os achados metabólicos da PET-CT foram menos eficientes que os resultados morfológicos da CT e RMN em pacientes com carcinoma hepatocelular tratados com microesferas marcadas com Ítrio-90, porém, foram mais significativos para o tratamento de metástases de câncer colorretal. De forma semelhante, outros estudos mostram que, apesar de serem divergentes em alguns casos, o RECIST e PERCIST são importantes critérios para predizer a resposta do câncer a tratamentos imunoterápicos 36 .…”

Section: Pet-ct/ 18 F-fdg No Monitoramento De Resultados Terapêuticosunclassified

Princípios básicos e aplicações oncológicas da PET-CT/18F-FDG

Dias

Carvalho

Pereira

2020

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

A Tomografia por Emissão de Pósitrons/Tomografia Computadorizada representa um grande salto tecnológico para a Medicina Nuclear e particularmente, para a Oncologia, visto que é capaz de distinguir alterações benignas e malignas com base em dados semiquantitativos da metabolização de radiofármacos pelos tecidos corporais. Este trabalho teve como objetivo realizar uma revisão narrativa dos principais levantamentos bibliográficos contemporâneos acerca dos princípios físicos da PET-CT/18F-FDG, suas aplicações na Oncologia e os avanços tecnológicos desta metodologia. Este trabalho foi elaborado com base em artigos obtidos de bancos de dados como PubMed, SciELO e Microsoft Academic Search, com descritores relacionados a PET-CT/18F-FDG e a Oncologia. A partir dos artigos analisados, observa-se que a PET-CT/18F-FDG é uma importante técnica para a obtenção de imagens morfofuncionais do corpo do paciente com sensibilidade e especificidade, muitas vezes, superiores aos métodos convencionais de diagnóstico por imagem. Dessa forma, a PET-CT/18F-FDG é recomendada nos casos de identificação e acompanhamento do estadiamento tumoral, monitoramento da taxa de resposta das terapias oncológicas e planejamento do alvo em tratamentos radioterápicos. Ainda, o desenvolvimento de algoritmos matemáticos e de sistemas de detecção de radiação mais eficientes na PET-CT/18F-FDG melhoram a qualidade da imagem e reduzem o tempo de exame.

show abstract

Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma

Cited by 13 publications

References 16 publications

Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

Personalized radioembolization for colorectal cancer patients with liver metastases

Princípios básicos e aplicações oncológicas da PET-CT/18F-FDG

Contact Info

Product

Resources

About